Trial Profile

QL1706 Combined With Platinum-based Chemotherapy Versus Placebo Combined With Platinum-based Chemotherapy as Adjuvant Therapy for Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection: a Randomized, Double-blind, Multicenter Phase III Clinical Study.

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 21 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Iparomlimab/tuvonralimab (Primary) ; Paclitaxel (Primary) ; Pemetrexed (Primary) ; Vinorelbine (Primary)
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Sponsors Qilu Pharmaceutical

14 Oct 2024 Planned End Date changed from 1 Oct 2031 to 22 May 2029.
14 Oct 2024 Planned primary completion date changed from 1 Oct 2028 to 31 Aug 2027.
08 Jun 2023 Status changed from not yet recruiting to recruiting, according to a Qilu Pharmaceutical media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com